Research and Markets has announced the addition of the "Vulvovaginal Candidiasis - Pipeline Review, H2 2016" report to their offering.
Vulvovaginal Candidiasis pipeline therapeutics constitutes close to 10 molecules. Out of which approximately 10 molecules are developed by Companies. Our latest report Vulvovaginal Candidiasis - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Vulvovaginal Candidiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Vulvovaginal Candidiasis refers to a disorder characterized by signs and symptoms of vulvovaginal inflammation in the presence of Candida species. Symptoms of vulvovaginal candidiasis include itching, soreness and/or burning discomfort in the vagina and vulva, heavy white curd-like vaginal discharge, bright red rash affecting inner and outer parts of the vulva, sometimes spreading widely in the groin to include pubic areas, inguinal areas and thighs. The molecules developed by Companies in Phase II, Phase I and Preclinical stages are 7, 2 and 1 respectively.
Furthermore, this report also reviews of key players involved in therapeutic development for Vulvovaginal Candidiasis and features dormant and discontinued projects.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/pg2v24/vulvovaginal
View source version on businesswire.com: http://www.businesswire.com/news/home/20161020006385/en/Business Wire
Last updated on: 20/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.